# **SAFETY DATA SHEETS**

This SDS packet was issued with item: 078778447

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078778439 078778454 078882556 078941619



Merck & Co., Inc. One Merck Dr. Whitehouse Station, NJ 08889

## MATERIAL SAFETY DATA SHEET

Merck Animal Health urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION					
MSDS NAME:	Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution				
SYNONYM(S):	RESFLOR (2-Pyrrolidone) Injectable Solution RESFLOR Injectable Solution - Reformulation RESFLOR (2-Pyrrolidone) Cattle Injectable RESFLOR Gold				
MSDS NUMBER:	SP001649				
EMERGENCY NUMBER(S):	(908) 423-6000 (24/7/365) English Only Emergencies - CHEMTREC: (800) 424-9300 (Inside Continental USA) (703) 527-3887 (Outside Continental USA)				
MERCK MSDS HELPLINE:	(800) 770-8878 (US and Canada) (908) 473-3371 (Worldwide) Monday to Friday, 9am to 5pm (US Eastern Time)				

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

### **EMERGENCY OVERVIEW**

Solution Yellow-brown Odor unknown Toxic by inhalation. May be harmful if swallowed. Irritating to eyes. May cause allergic reactions in susceptible individuals. May cause effects to: gastrointestinal tract respiratory system blood liver kidnev male reproductive system fetus May cause impaired fertility. May cause developmental effects. Toxic to aquatic organisms. May cause long-term adverse effects in the aquatic environment.

### POTENTIAL HEALTH EFFECTS:

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s).

Florfenicol is a broad spectrum antibiotic used in veterinary products. Florfenicol may cause allergic reactions in susceptible individuals. Based on animal studies, florfenicol may cause slight eye irritation, constipation, changes in blood cell counts, changes in stool, or liver effects. It may also cause developmental effects or effects to male reproductive organs.

Flunixin meglumine is a potent non-narcotic, non-steroidal agent with pain killing, anti-inflammatory, and fever-reducing activity. Based on animal studies, flunixin meglumine may cause severe eye irritation or irreversible ocular effects. It may also cause irritation of the skin, mucous membranes, respiratory tract, and gastrointestinal tract. Repeated dermal contact to high concentrations may cause severe skin irritation. Prolonged inhalation may produce serious lung effects. Repeated ingestion or inhalation of high doses may cause internal bleeding, predominantly of the gastrointestinal tract.

Glyceryl triacetate may cause slight to moderate eye irritation based on animal studies.

2-Pyrrolidone may cause fetal effects based on animal studies.

Malic acid is a relatively strong acid. It may cause severe eye irritation, and skin and mucous membrane irritation.

## LISTED CARCINOGENS

No carcinogens or potential carcinogens listed by OSHA, IARC, NTP or ACGIH are present in concentrations >0.1% in this mixture.

## SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

PRODUCT USE:

Veterinary product

Mixture.

CHEMICAL FORMULA:

The formulation for this product is proprietary information. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 2.

## **CHEMICAL COMPOSITION**

**MSDS NAME:** Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution Latest Revision Date: 20-Jan-2012

### MSDS NUMBER: SP001649

Page 2 of 9

INGREDIENT	CAS NUMBER	PERCENT
Florfenicol	73231-34-2	25
Glyceryl Triacetate	102-76-1	40-50
2-Pyrrolidone	616-45-5	20-30
Malic Acid	6915-15-7	<10
Flunixin Meglumine	42461-84-7	2.2

ADDITIONAL INFORMATION:	This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.			
	SECTION 4. FIRST AID MEASURES			
INHALATION:	Remove to fresh air. Administer artificial respiration if breathing has ceased. IMMEDIATELY consult a physician.			
SKIN CONTACT:	In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.			
EYE CONTACT:	In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.			
INGESTION:	Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Center. If symptoms persist, consult a physician.			
NOTE TO PHYSICIAN:	This product contains florfenicol, a broad spectrum antibiotic which may cause allergic reactions in susceptible individuals. Flunixin meglumine is a potent Non-Steroidal Anti-inflammatory Drug (NSAID), and overexposure may cause gastrointestinal irritation and bleeding, kidney and central nervous system effects.			

## **SECTION 5. FIRE FIGHTING MEASURES**

### FLAMMABILITY DATA:

Flash Point:

Not determined (liquids) or not applicable (solids).

### SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

### SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO2), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

#### PERSONAL PRECAUTIONS:

Wear appropriate personal protective equipment as specified in Section 8. Keep personnel away from the clean-up area.

#### SPILL RESPONSE / CLEANUP:

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. For laboratories and small-scale operations, incidental spills within a hood or enclosure should be cleaned by using a HEPA filtered vacuum or wet cleaning methods as appropriate. For large dry or liquid spills or those spills outside enclosure or hood, appropriate emergency response personnel should be notified. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

#### **ENVIRONMENTAL PRECAUTIONS:**

This product is toxic to aquatic organisms. Do not allow product to reach ground water, water course, sewage or drainage systems.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

## SECTION 7. HANDLING AND STORAGE

#### HANDLING:

Keep containers adequately sealed during material transfer, transport, or when not in use. Wash face, hands, and any exposed skin after handling. Do not eat, drink, or smoke when using this substance or mixture.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

#### STORAGE:

Store in a cool, dry, well ventilated area.

See Section 8 for exposure controls and additional safe handling information.

## **SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION**

The following guidance applies to the handling of the active ingredient(s) in this formulation.

#### OCCUPATIONAL EXPOSURE BAND (OEB):

OEB 3: 10-100 mcg/m<sup>3</sup>. Materials in an OEB 3 category are considered moderate health hazards. The OEB is a range of airborne concentrations expressed as an 8-hour Time Weighted Average (8-hr. TWA) and is intended to be used with Industrial Hygiene Risk Assessment to assist with industrial hygiene sampling and selection of proper controls for worker protection. Consult your site safety and industrial hygiene staff for guidance on handling and control strategies.

#### **OCCUPATIONAL EXPOSURE GUIDELINE (OEG):**

An Occupational Exposure Guideline (OEG) of 80 mcg/m<sup>3</sup> (8-hr TWA) has been established for Florfenicol. Consult your site safety and industrial hygiene professional(s) for additional guidance.

An Occupational Exposure Guideline (OEG) of 18 mcg/m<sup>3</sup> (8-hr TWA) has been established for flunixin. Consult your site safety and industrial hygiene professional(s) for additional guidance.

#### **OEB/OEL NOTATION(S):**

Florfenicol: This material has a notation of "A" for its ability to cause immediate allergic hypersensitivity reactions or anaphylaxis.

Flunixin Meglumine: This material has a notation of "C" for corrosivity.

#### **EXPOSURE CONTROLS**

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

### **RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):**

Respiratory Protection:	Respiratory protective equipment (RPE) may be required for certain laboratory and large-scale manufacturing tasks if potential airborne breathing zone concentrations of substances exceed the relevant exposure limit(s). Workplace risk assessment should be completed before specifying and implementing RPE usage. Potential exposure points and pathways, task duration and frequency, potential employee contact with the substance, and the ability of the substance to be rendered airborne during specific tasks should be evaluated. Initial and ongoing strategies of quantitative exposure measurement should be obtained as required by the workplace risk assessment. All RPE must conform to local and regional specifications for efficacy and performance. Consult your site or corporate health and safety professional for additional guidance.
Skin Protection:	Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
Eye Protection:	Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard, potential for contact, or level of exposure. Consult your site safety staff for guidance.
Body Protection:	In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.
	In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.
NAME: Florfenicol (300 mg/mL)-Flun	xin MSDS NUMBER: SP001649

**MSDS NAME:** Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution Latest Revision Date: 20-Jan-2012

### **EXPOSURE LIMIT VALUES**

See Occupational Exposure Guideline (OEG) listed above.

### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

FORM: COLOR: ODOR: SPECIFIC GRAVITY: SOLUBILITY: Water: Solution Yellow-brown Odor unknown 1.22

Not determined

See Section 5 for flammability/explosivity information.

### SECTION 10. STABILITY AND REACTIVITY

### STABILITY/ REACTIVITY:

Stable under normal conditions.

# INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID: None known.

#### HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:

No dangerous decomposition is expected if used according to manufacturer's specifications.

### SECTION 12. ECOLOGICAL INFORMATION

There are no data for the final product or its formulation(s). The information presented below pertains to the following ingredient(s).

### ECOTOXICITY DATA

INGREDIENT ECOTOXICITY

Florfenicol: 96-hr LC50 (bluegill): >830 mg/L Florfenicol: 96-hr LC50 (trout): >780 mg/L Florfenicol: 48-hr EC50 (daphnid): >330 mg/L Florfenicol: Algae maximum cell density: MIC = 1.5 mg/L Florfenicol: Algae maximum growth rate: MIC >2.9 mg/L

Flunixin meglumine: 96-hr LC50 (trout): 9.2 mg/L Flunixin meglumine: 96-hr LC50 (bluegill): 46 mg/L Flunixin meglumine: 48-hr EC50 (Daphnia): 25 mg/L Flunixin meglumine: 72 hr IC50 (Algae): 36-120 mg/L

### ENVIRONMENTAL DATA

OTHER INGREDIENT ENVIRONMENTAL DATA:

Florfenicol: log Pow (log octanol/water partition coefficient): 2.36 Florfenicol: Solubility 1.32 mg/ml at pH 7 Florfenicol: Biodegrability: Not readily biodegradable but there is evidence of inherent biodegradability.

Flunixin Meglumine: log Pow (log octanol/water partition coefficient): 1.34

Glyceryl Triacetate: log Pow (log octanol/water partition coefficient): 0.25 Glyceryl triacetate is not expected to bioaccumulate or bioconcentrate in aquatic organisms. The estimated BCF is 1.3. It is expected to hydrolyse in soil and water to rapidly biodegradable products.

Malic Acid: log Pow (log octanol/water partition coefficient): -1.26

### ENVIRONMENTAL FATE AND EFFECTS:

Photolytic half-life of Florfenicol in synthetic humic water (SHW) or pure water (PW) was 196 days in SHW and 171 days in PW.

## SECTION 11. TOXICOLOGICAL INFORMATION

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. The information presented below pertains to the following individual ingredients, and not to the mixture(s).

**MSDS NAME:** Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution Latest Revision Date: 20-Jan-2012

MSDS NUMBER: SP001649

Page 5 of 9

### ACUTE TOXICITY DATA

#### INHALATION:

Florfenicol: No mortality occurred in rats exposed to florfenicol for 4 hours at 0.28 mg/L (the maximum concentration tested). Clinical effects included dry rales, anogenital staining, secretory discharge, soft stool, and decreased body weights. These effects were seen immediately or up to one-week post exposure. Some effects did not resolve by study termination.

#### Flunixin Meglumine: Inhalation LC50 (4hr): <0.52 mg/L (rat)

Mortality occurred in all rats (10/10) between days 3 and 6 following a single 4-hour exposure to an average analytical concentration of 0.52 mg/L (maximum attainable exposure). Signs exhibited following exposure included lacrimation, nasal discharge, dried red material around facial area, and yellow anogenital staining. Significant weight loss was noted following exposure in all animals.

#### SKIN:

Florfenicol was not irritating to rabbit skin.

### Flunixin meglumine: Slightly irritating

Flunixin meglumine produced mild, transient dermal irritation in rabbits. Dose-related skin irritation effects were observed in rabbits during a 21-day repeat skin application study (see below under Subchronic to Chronic Toxicity).

Glyceryl triacetate was not irritating when absorbed through the skin of guinea pigs.

2-Pyrrolidone was not irritating to the skin of rabbits.

Malic acid was moderately irritating to the skin of rabbits, and strongly irritating to the skin of guinea pigs.

#### EYE:

Florfenicol was slightly irritating to the eyes of rabbits.

#### Flunixin Meglumine: Severely irritating

All six animals exhibited severe conjunctival irritation including redness, swelling, discharge, and necrosis, as well as corneal opacity, ulceration and iridial damage. Severe ocular irritation was irreversible in most animals.

Rabbits treated with 0.1 ml of undiluted glyceryl triacetate exhibited slight to moderate irritation, but produced no effect when immediately rinsed for six minutes.

2-Pyrrolidone was not irritating to the eyes of rabbits.

Malic acid was severely irritating to the eyes of rabbits.

#### ORAL:

Florfenicol: Oral LD50: >2000 mg/kg (rat, mouse).

Dogs (one animal/sex) were administered successive oral doses of florfenicol that ranged from 160 to 1280 mg/kg. No clinical effects occurred at doses as high as 640 mg/kg. At 640 mg/kg, the only female died from inhalation of vomitus. Vomiting or soft stool occurred at 640 to 1280 mg/kg.

Flunixin Meglumine: Oral LD50: 53 to 157 mg/kg (rat), 176 to 249 mg/kg (male mouse, female estimated)

Flunixin (free acid): Oral LD50: 468.3 mg/kg (guinea pig)

Common effects observed in acute oral studies across species include gastrointestinal effects (perforation/ulceration and hemorrhage), hypoactivity, pallor, spleen enlargement, congestion of kidneys, lungs, or gastrointestinal tract, and respiratory distress. Necropsy of animals that died from flunixin meglumine revealed abnormalities of the brain, epididymides, abdominal cavity, thymus, liver, mesenteric lymph nodes, esophagus, mesentery, pancreas, and lungs. No signs of toxicity were observed following acute oral administration of 100 & 200 mg/kg to rhesus monkeys. However, 1 of 3 monkeys died following administration of 300 mg/kg. That monkey showed lethargy, prostration, and salivation prior to death, and signs of hyperemic mucosa in gastrointestinal tract and lungs at necropsy. Flunixin administered orally to mice at a dose of 300 mg/kg (100x the projected clinical dose) caused slight tremors and ataxia which resolved within 24 hours. Effects from acute oral and IV treatment of horses with 1.1 mg/kg flunixin were limited to sporadic incidence of fecal occult blood.

Glyceryl triacetate: Oral LD50: 3000-12800 mg/kg (rat); 1100-6100 mg/kg (mouse). Symptoms observed during the determination of the oral LD50 in rats and mice were weakness and ataxia.

2-Pyrrolidone: Oral LD50: 328-6500 mg/kg (rat); 6500 mg/kg (guinea pig)

### Malic Acid: Oral LD50: > 3200 mg/kg (rat); 1600-3200 mg/kg (mouse)

Signs of acute poisoning in rats and mice are weakness, retraction of the abdomen, respiratory distress, and cyanosis.

### DERMAL AND RESPIRATORY SENSITIZATION:

Flunixin Meglumine was found not to be sensitizing in guinea pigs when tested by intradermal induction at 1% and topically at 100%.

Glyceryl triacetate was not a skin sensitizer in guinea pigs.

### ADDITIONAL INFORMATION:

Florfenicol: Intaperitoneal LD50: 1913-2253 mg/kg (rat)

Clinical signs of toxicity noted in rats treated with 1000 to 2000 mg/kg florfenicol included hypoactivity, wet or stained urogenital hair, chromorhinorrhea, or discolored stool. Abnormal pathological findings in rats included white, granular foci on surface of the liver or intestines, or pale or friable kidneys (high dose group).

#### **REPEAT DOSE TOXICITY DATA**

#### SUBCHRONIC / CHRONIC TOXICITY:

Florfenicol was administered orally to dogs, rats, and mice at dosages as high as 100 to 400 mg/kg/day for up to 13 weeks. Effects including decreased body weight, changes in liver weight or liver enzyme levels, changes in testicular weight, testicular atrophy, decreased white blood cell counts, and decreased hemoglobin levels were observed at high dosages. Cellular changes in the liver or lymph nodes of rats and mice, and histopathologic changes in the brain and spinal cord of dogs were also noted at these high dosages. Although some effects were reversible after a 4-week withdrawal from treatment, testicular effects in rats persisted. Intramuscular injections of 45 mg/kg of florfenicol in swine produced diarrhea, injection site lesions, decreased body weight, decreased food and water consumption, changes in serum electrolytes and proteins, decreased red blood cell and white blood cell counts, decreased spleen weight, and decreased kidney weight.

In 52-week oral toxicity studies in dogs and rats, high dosages of florfenicol (12 and 48 mg/kg/day, respectively) increased liver weight and produced cellular changes in the gall bladder of dogs. In rats, florfenicol at the high dosage reduced body weight gain, reduced testicular weight, induced changes in hematologic and clinical chemistry parameters, and increased the incidence of testicular tubular atrophy. In two-year chronic studies in mice and rats, florfenicol caused similar effects as those observed in other long-term studies including reduced body weight gain, reduced red blood cell count, reduced hemoglobin levels, and testicular effects such as small testes, tubular atrophy and aspermatogenesis in both the high dosage rats (48 mg/kg/day) and mice (200 mg/kg/day).

Repeat oral dosing studies have been performed with flunixin across multiple species. The most common adverse effect seen in these studies is gastrointestinal irritation/ulceration and bleeding as indicated by blood in the stools. Other common adverse effects observed across species from oral, IV or IM routes of exposure include nephrotoxicity, emesis, anorexia, and bleeding. Blood cell count changes, blood coagulation effects, and immune organ effects were observed secondary to gastrointestinal erosion and bleeding. Liver, nervous system and behavioral effects were also noted in mice. In addition to ulceration and bleeding, significant mortality was observed in rats at 8 and 16 mg/kg dosed for six weeks. [6-week oral toxicity NOAEL: 2 mg/kg (rats); 90-day oral toxicity NOAEL: 5 mg/kg (monkeys), 3.0 mg/kg (rats); one year oral toxicity NOEL: 1 mg flunixin/kg (rats)]

In several 21-day repeat skin application studies in rabbits using up to 80 mg/kg flunixin meglumine or the free acid in spray or cream formulations, no conclusive treatment-related toxicity could be established. The incidence and severity of dermal irritation increased in a dose-related manner with severe irritation seen at 80 mg/kg/day.

Rats exposed to inhalation doses of glyceryl triacetate at 250 ppm for 13 weeks, and saturated vapors for 5 days, produced no symptoms or histopathological effects.

#### **REPRODUCTIVE / DEVELOPMENTAL TOXICITY:**

In a two-generation reproductive study, oral administration as high as 12 mg/kg/day of florfenicol reduced epididymal weights, decreased pup survival, and reduced lactation index in rats [NOAEL: 3 mg/kg/day].

There was no evidence of teratogenicity in rats administered florfenicol at dosages of 4, 12 or 40 mg/kg/day. Slight maternal toxicity, evidenced by decreased food and water consumption, was observed above 4 mg/kg/day. At 40 mg/kg/day, an increased incidence of delayed ossification and decreased fetal weight occurred. The NOAEL for maternal and fetal toxicity in rats was determined to be 4 mg florfenicol/kg/day.

Two teratogenicity studies were performed in mice. In the first study, the mice were administered florfenicol at dosages of 40, 120, or 400 mg/kg by gavage on days 6-15 of gestation. Florfenicol produced embryolethality at the 400 mg/kg/day dose level, which was evidenced by the high incidence of intrauterine deaths. Significant decreases in mean fetal body weight, soft tissue defects, and retarded skeletal ossification were also observed at 400 mg/kg/day. Skeletal ossification was less pronounced, in a dose-related fashion, at the lower doses tested (40 and 120 mg/kg/day). A developmental NOAEL could not be determined for these data [NOAEL for maternal: 120 mg/kg]. In the second teratogenicity study, florfenicol was retested at lower administered dosages of 1, 3, or 60 mg/kg/day. Maternal effects were limited to a slight increase in water consumption at the 60 mg/kg/day dose. There was no evidence of any adverse effects on the embryo/fetus at doses as high as 60 mg/kg/day in this study. However, based upon the retarded skeletal ossification effects observed in the first study at 40 mg/kg/day the NOAEL for the two studies combined was determined to be between 3 and 40 mg/kg/day.

Reproductive and teratology studies in rats, mice and rabbits were performed with flunixin. Although significant maternal toxicity, including mortality, was reported, these studies indicate that flunixin does not affect offspring development, male or female fertility, or mating behavior. A slight increase in the length of gestation and difficult labor with an increase in stillbirths were observed. No evidence of any drug-related teratogenic effects were observed. Maternal toxicity observed in these studies was consistent with those findings in acute and repeated dose oral toxicity studies with the addition of pale eyes, ears and extremities. [Reproductive or developmental NOELs ranged from 2-21 mg/kg in studies with multiple species. Maternal toxicity NOELs ranged from 3-9 mg/kg in these studies].

2-Pyrrolidone was embryotoxic but not teratogenic in mice exposed through oral and intraperitoneal routes of exposure. Maternal toxicity and malformations were observed in rats orally administered 1900 mg/kg/day. In a study conducted in rats, the inhalation of 150 ppm of 2-pyrrolidone on days 7 to 20 of gestation was associated with decreased pup weights and delays in developmental milestones.

#### **MUTAGENICITY / GENOTOXICITY:**

Florfenicol was negative in a bacterial mutagenicity study (Ames), a mammalian mutagenicity study (mouse lymphoma), a bone marrow micronucleus assay, an in vitro chromosomal aberration assay in CHO cells, a cytogenetics assay in bone marrow, and an unscheduled DNA synthesis assay in rat hepatocytes.

Flunixin meglumine was negative in the Ames and mouse micronucleus assays. It was positive in mouse lymphoma L5178Y cells, both in the absence and presence of S-9 metabolic activation and in the chromosomal abberation assay in CHO cells in vitro both in the absence and presence of S-9 metabolic activation. It has been reported to alter cellular DNA and caused primary DNA damage in E. coli. Flunixin free acid yielded the same results as flunixin meglumine. However, it was inconclusive in the bacterial repair assay in E.coli whereas flunixin meglumine was strongly positive. The meglumine moiety (N-methyl-D glucamine) was negative in all studies performed except the micronucleus study in which it was positive in one study and negative in a second.

2-Pyrrolidone was not mutagenic in a bacterial mutagenicity assay (Ames).

Malic acid was negative in bacterial mutagenicity studies (Ames), either in the absence or presence of metabolic activation. Malic acid was not clastogenic in Chinese hamester fibroblast cells.

#### CARCINOGENICITY:

Florfenicol was not carcinogenic in a 2-year study in rats administered dosages up to 48 mg/kg/day for 5 days a week or in mice at dosages up to 200 mg/kg/day for 5 days per week.

Flunixin meglumine had no carcinogenic effects or increase in tumor incidence relative to controls in either a 104-week study in rats administered 2, 4 and 8 mg flunixin meglumine/kg/day in the diet, or in mice administered 0.6, 2.0 and 6.0 mg flunixin meglumine/kg/day in the diet for 97 weeks. Significant toxicity observed in rats and mice included decreased body weights, increased mortality (high dose groups) and dose-related increases in gastrointestinal lesions in all treated groups. Compound-related lesions observed at necropsy included dose-related gastrointestinal ulcers, ulcer perforation with secondary peritonitis and adhesion formation, and large or edematous lymph nodes. Dose-related nonproliferative lesions were present in the gastrointestinal tract and mesenteric lymph node. Necrosis and ulceration of the mucosa, transmural necrosis, mucosal and mural inflammation, lymphoid hyperplasia, peritonitis and abscess formation were present. Inflammatory lesions and necrosis secondary to the peritonitis were present in other abdominal organs. Splenomegaly (enlarged spleens) were observed at necropsy in mice and were significant in the high dose group only. [Rat NOEL for tumor formation = 8 mg flunixin meglumine/kg/day and the LOEL = 2 mg flunixin meglumine/kg/day based on GI lesions. Mouse NOEL for tumor formation = 6.0 mg flunixin meglumine/kg/day; Toxicity NOEL = 0.6 mg flunixin meglumine/kg/day].

### **SECTION 13. DISPOSAL CONSIDERATIONS**

#### MATERIAL WASTE:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

### PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

#### SPECIAL ENVIRONMENTAL HANDLING PROCEDURES:

This product contains materials that are harmful to the environment. Do not allow undiluted/unneutralized product to reach ground water, water course, sewage or drainage systems.

### **SECTION 14. TRANSPORT INFORMATION**

This material is not subject to the transportation regulations of DOT, IATA, IMO, and the ADR.

### SECTION 15. REGULATORY INFORMATION

### **TSCA LISTING**

INGREDIENT	TSCA
Glyceryl Triacetate	Х
2-Pyrrolidone	Х
Malic Acid	Х

Substances not included in the table above are TSCA exempt or not regulated under TSCA.

## **U.S. STATE REGULATIONS**

INGREDIENT	California Proposition 65	CARTK	NJRTK	CTRTK	MARTK
2-Pyrrolidone					Х

**MSDS NAME:** Florfenicol (300 mg/mL)-Flunixin (16.5 mg/mL)-2-Pyrrolidone Injectable Solution Latest Revision Date: 20-Jan-2012

INGREDIENT	PARTK	MNRTK	MIRTK	RIRTK
2-Pyrrolidone	Х			

Fields in the above tables that do not contain data indicate that those materials have not been listed by local regulations.

X: Listed on applicable state hazardous substance or right-to-know lists.

## **SECTION 16. OTHER INFORMATION**

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

The brand-names or trademarks indicated by CAPITAL LETTERS in this [M]SDS are the property of, licensed to, promoted or distributed by Merck & Co., Inc., its subsidiaries or related companies.

DEPARTMENT ISSUING MSDS:	Global Safety & the Environment Merck & Co., Inc. One Merck Drive Whitehouse Station, NJ 08889
MERCK MSDS HELPLINE:	(800) 770-8878 (US and Canada) (908) 473-3371 (Worldwide) Monday to Friday, 9am to 5pm (US Eastern Time)
MSDS CREATION DATE:	13-Apr-2006
SUPERSEDES DATE:	07-May-2010
SECTIONS CHANGED (US SUBFORMAT): SIGNIFICANT CHANGES (US SUBFORMAT):	2, 11 OEB



Version 8.1	Revision Date: 03/23/2020		OS Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014			
SECTION	1. IDENTIFICATION						
Prod	uct name	:	Florfenicol / Flu	nixin Formulation			
Man	ufacturer or supplier's	deta	ails				
Com Addr Teler Telef Eme	pany name of supplier ess ohone	: :	<ul> <li>Merck &amp; Co., Inc</li> <li>2000 Galloping Hill Road Kenilworth - New Jersey - U.S.A. 07033</li> <li>908-740-4000</li> <li>908-735-1496</li> </ul>				
				WARD@merck.com			
	ommended use of the c ommended use	nen.	Veterinary prod				
		•					
SECTION	2. HAZARDS IDENTIF		ΓΙΟΝ				
CUS	alocaification in accor	don	oo with 20 CEP	1010 1300			
	classification in accor e toxicity (Oral)	uan	Category 4	1910.1200			
Acut		•	0 1				
Acute	e toxicity (Inhalation)	:	Category 4				
Eye i	rritation	:	Category 2A				
Repr	oductive toxicity	:	Category 1B				
	ific target organ toxicity eated exposure	:	Category 1 (Live Gastrointestinal	er, Brain, Testis, Spinal cord, Blood, gallbladder tract, Kidney)			
GHS	label elements						
Haza	ard pictograms	:		!			
Signa	al Word	:	Danger				
Haza	ard Statements	:	<ul> <li>H302 + H332 Harmful if swallowed or if inhaled.</li> <li>H319 Causes serious eye irritation.</li> <li>H360FD May damage fertility. May damage the unborn chile</li> <li>H372 Causes damage to organs (Liver, Brain, Testis, Spina cord, Blood, gallbladder, Gastrointestinal tract, Kidney) throprolonged or repeated exposure.</li> </ul>				
Prec	autionary Statements	:	P202 Do not ha and understood P260 Do not br P264 Wash skir	ecial instructions before use. ndle until all safety precautions have been read eathe mist or vapors. n thoroughly after handling. t, drink or smoke when using this product.			



sion	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
			y outdoors or in a well-ventilated area. otective gloves/ protective clothing/ eye protection n.
		CENTER/ doc P304 + P340 - and keep com doctor if you fe P305 + P351 - for several mir to do. Continu P308 + P313 I attention.	<ul> <li>+ P338 IF IN EYES: Rinse cautiously with water nutes. Remove contact lenses, if present and easy</li> </ul>
		<b>Storage:</b> P405 Store loo	cked up.
		<b>Disposal:</b> P501 Dispose posal plant.	of contents/ container to an approved waste dis-
	<b>hazards</b> known.		

Substance / Mixture : Mixture

Chemical name	CAS-No.	Concentration (% w/w)
Florfenicol	73231-34-2	>= 20 - < 30
2-Pyrrolidone	616-45-5	>= 20 - < 30
Malic Acid	6915-15-7	>= 1 - < 5
1-Deoxy-1-(methylamino)-D-glucitol	42461-84-7	>= 1 - < 5
2-[2-methyl-3-		
(perfluoromethyl)anilino]nicotinate		
Actual concentration is withheld as a	trade secret	

Actual concentration is withheld as a trade secret

## **SECTION 4. FIRST AID MEASURES**

General advice	<ul> <li>In the case of accident or if you feel unwell, seek medical advice immediately.</li> <li>When symptoms persist or in all cases of doubt seek medical advice.</li> </ul>
If inhaled	<ul> <li>If inhaled, remove to fresh air.</li> <li>If not breathing, give artificial respiration.</li> <li>If breathing is difficult, give oxygen.</li> <li>Get medical attention.</li> </ul>
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty



Version 8.1	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
		Get medica Wash clothi	ntaminated clothing and shoes. I attention. ng before reuse. clean shoes before reuse.
In ca	se of eye contact	: In case of c for at least	ontact, immediately flush eyes with plenty of water 15 minutes. o, remove contact lens, if worn.
lf swa	If swallowed		d, DO NOT induce vomiting. I attention. h thoroughly with water. anything by mouth to an unconscious person.
	important symptoms effects, both acute and /ed	: Harmful if s Causes ser May damag	wallowed or if inhaled. ious eye irritation. e fertility. May damage the unborn child. nage to organs through prolonged or repeated
Prote	ection of first-aiders	: First Aid res and use the	ponders should pay attention to self-protection, recommended personal protective equipment ptential for exposure exists (see section 8).
Note	s to physician		tomatically and supportively.
SECTION	5. FIRE-FIGHTING ME	ASURES	
Suita	ble extinguishing media	: Water spray Alcohol-res Carbon dioz Dry chemic	stant foam kide (CO2)

		Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Fluorine compounds Nitrogen oxides (NOx)
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
Environmental precautions	:	Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or



Version 8.1	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
			ose of contaminated wash water. s should be advised if significant spillages ined.
	ds and materials for ment and cleaning up	For large spills, containment to k can be pumped, container. Clean up remain absorbent. Local or national disposal of this r employed in the determine which Sections 13 and	ert absorbent material. provide diking or other appropriate keep material from spreading. If diked material store recovered material in appropriate ning materials from spill with suitable I regulations may apply to releases and material, as well as those materials and items cleanup of releases. You will need to a regulations are applicable. 15 of this SDS provide information regarding mational requirements.

## SECTION 7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	<ul> <li>Do not get on skin or clothing.</li> <li>Do not breathe vapors or spray mist.</li> <li>Do not swallow.</li> <li>Do not get in eyes.</li> <li>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</li> <li>Keep container tightly closed.</li> <li>Take care to prevent spills, waste and minimize release to the</li> </ul>
Conditions for safe storage	<ul> <li>environment.</li> <li>Keep in properly labeled containers.</li> <li>Store locked up.</li> <li>Keep tightly closed.</li> <li>Keep in a cool, well-ventilated place.</li> <li>Store in accordance with the particular national regulations.</li> </ul>
Materials to avoid	<ul> <li>Do not store with the following product types:</li> <li>Strong oxidizing agents</li> <li>Organic peroxides</li> <li>Explosives</li> <li>Gases</li> </ul>

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
------------	---------	-------------------------------------	--	-------



sion	Revision Date: 03/23/2020	SDS Number: 28058-00016		Date of last Date of firs		
Florfer	nicol		73231-34-2	TWA	100 µg/m3 (OEB 2)	Internal
glucito (perflu	xy-1-(methylamino)-D- l 2-[2-methyl-3- orome- ilino]nicotinate		42461-84-7	TWA	40 µg/m3 (OEB 3)	Internal
	-			Wipe limit	400 µg/100 cm <sup>2</sup>	Internal
Engin	eering measures	<ul> <li>Use appropriate engineering controls and manufacturin technologies to control airborne concentrations (e.g., du less quick connections).</li> <li>All engineering controls should be implemented by facil design and operated in accordance with GMP principle protect products, workers, and the environment.</li> <li>Containment technologies suitable for controlling comp are required to control at source and to prevent migration the compound to uncontrolled areas (e.g., open-face containment devices).</li> <li>Minimize open handling.</li> </ul>				g., drip- facility ciples to ompounds gration of
Perso	nal protective equipm	ent	:			
	atory protection		maintain vapo concentrations unknown, app Follow OSHA use NIOSH/M by air purifying hazardous cho supplied respi release, expos	or exposures belo s are above reco propriate respirat respirator regula SHA approved r g respirators aga emical is limited irator if there is a sure levels are u where air purifyi	ntilation is recommen ow recommended lim ory protection should ations (29 CFR 1910. respirators. Protection ainst exposure to any . Use a positive press any potential for unco inknown, or any othe ng respirators may no	its. Where re be worn. 134) and provided sure air ntrolled r
Mat	terial	:	Chemical-resi	stant gloves		
	marks otection	:	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty condition mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.			ere is a
Skin ai	nd body protection	:	Work uniform Additional boo task being per disposable su	formed (e.g., sle its) to avoid exp ate degowning te	at. uld be used based up eevelets, apron, gaun osed skin surfaces. echniques to remove	itlets,
Hygier	ne measures	:	If exposure to eye flushing s working place When using d	chemical is likel ystems and safe		



Versio 8.1	n Revision Date: 03/23/2020		S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
			engineering contr appropriate dego	ration of a facility should include review of ols, proper personal protective equipment, wning and decontamination procedures, e monitoring, medical surveillance and the tive controls.
SECTI	ON 9. PHYSICAL AND CHI	EMIC		S
A	ppearance	:	liquid	
С	olor	:	yellow	
0	dor	:	No data available	e
0	dor Threshold	:	No data available	e
pl	4	:	No data available	e
Μ	elting point/freezing point	:	No data available	e
	itial boiling point and boiling inge	:	No data available	e
FI	ash point	:	No data available	e
E	vaporation rate	:	No data available	e
F	ammability (solid, gas)	:	Not applicable	
F	ammability (liquids)	:	No data available	e
	pper explosion limit / Upper ammability limit	:	No data available	e
	ower explosion limit / Lower ammability limit	:	No data available	e
V	apor pressure	:	No data available	e
R	elative vapor density	:	No data available	e
R	elative density	:	1.22	
D	ensity	:	No data available	e
S	olubility(ies) Water solubility	:	No data available	e
	artition coefficient: n-	:	Not applicable	
	ctanol/water utoignition temperature	:	No data available	e
D	ecomposition temperature	:	No data available	e
V	iscosity			

## SAFETY DATA SHEET



## **Florfenicol / Flunixin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2019
8.1	03/23/2020	28058-00016	Date of first issue: 11/04/2014
	scosity, kinematic sive properties	: No data avai : Not explosive	
Oxidizing properties		: The substand	ce or mixture is not classified as oxidizing.
Particle size		: Not applicabl	le

## SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.
tions		
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition	:	No hazardous decomposition products are known.
products		

## SECTION 11. TOXICOLOGICAL INFORMATION

## Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

## Acute toxicity

Harmful if swallowed or if inhaled.

## Product:

Acute oral toxicity	:	Acute toxicity estimate: 1,320 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 2.28 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Components:		
Florfenicol:		
Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg
		LD50 (Mouse): > 2,000 mg/kg
		LD50 (Dog): > 1,280 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 0.28 mg/l Exposure time: 4 h
Acute dermal toxicity	:	Remarks: No data available



rsion	Revision Date: 03/23/2020		0S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
Acute toxicity (other routes of administration)		:	LD50 (Rat): 1,913 Application Route	
			LD50 (Mouse): 10 Application Route	
2-Pyrr	olidone:			
	oral toxicity	:	LD50 (Rat): > 2,00 Method: OECD Te Assessment: The icity	
Acute	dermal toxicity	:	LD50 (Rabbit): > 2 Method: OECD Te Assessment: The toxicity	
Malic	Acid:			
Acute	oral toxicity	:	LD50 (Rat): 3,500	mg/kg
Acute	dermal toxicity	:	LD50 (Rabbit): > Remarks: Based o	5,000 mg/kg on data from similar materials
1-Deo	xy-1-(methylamino)-D-	glu	citol 2-[2-methyl-3	3-(perfluoromethyl)anilino]nicotinate:
Acute	oral toxicity	:	LD50 (Rat): 53 - 1	57 mg/kg
			LD50 (Mouse): 17	'6 - 249 mg/kg
			LD50 (Guinea pig	): 488.3 mg/kg
			LD50 (Monkey): 3	00 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): < 0.52 Exposure time: 4 Test atmosphere:	h
	toxicity (other routes of istration)	:	LD50 (Rat): 59.4 - Application Route	0 0
			LD50 (Mouse): 16 Application Route	
	corrosion/irritation assified based on availa	ble	information.	
<u>Comp</u>	onents:			
Florfe	nicol:			
Specie	es	:	Rabbit	

Species	:	Rabbit
Result	:	No skin irritation

## 2-Pyrrolidone:



rsion	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014		
Species Method Result		: Rabbit : OECD Test Gu : No skin irritatio			
Malic	Acid:				
Speci	es	: Rabbit			
Metho		: OECD Test Gu			
Resul Rema		: No skin irritatio : Based on data	n from similar materials		
1-Dec	oxy-1-(methylamino)	-D-glucitol 2-[2-meth	yl-3-(perfluoromethyl)anilino]nicotinate:		
Speci		: Rabbit			
Resul	lt	: Mild skin irritati	on		
	us eye damage/eye				
	es serious eye irritatio <b>conents:</b>	on.			
	enicol:				
Speci		: Rabbit			
Resul		: Mild eye irritati	on		
2-Pyr	rolidone:				
Speci		: Rabbit			
Resul	t	: Irritation to eye	s, reversing within 7 days		
Malic	Acid:				
Speci		: Rabbit			
Resul Metho		-	s, reversing within 21 days		
Rema			<ul><li>OECD Test Guideline 405</li><li>Based on data from similar materials</li></ul>		
1-Dec	oxy-1-(methylamino)	-D-glucitol 2-[2-meth	yl-3-(perfluoromethyl)anilino]nicotinate:		
Speci		: Rabbit			
Resul	t	: Irreversible effe	ects on the eye		
Resp	iratory or skin sensi	tization			
-	sensitization				
Not cl	assified based on ava	ailable information.			
-	iratory sensitization assified based on ava				
	oonents:				
Florfe	enicol:				
Test		: Maximization T	- est		

Test Type	:	Maximization Test
Species	:	Guinea pig
Result	:	negative



Version 8.1	Revision Date: 03/23/2020	SDS Number:Date of last issue: 12/12/201928058-00016Date of first issue: 11/04/2014
2-Pyr	rolidone:	
Test	Гуре	: Local lymph node assay (LLNA)
	es of exposure	: Skin contact
Speci		: Mouse
Metho		: OECD Test Guideline 429
Resul Rema		: negative : Based on data from similar materials
Reine		
Malic	Acid:	
Test		: Maximization Test
	es of exposure	: Skin contact
Speci		: Guinea pig
Metho Resul		: OECD Test Guideline 406
Resul		: negative : Based on data from similar materials
Reme		
		-D-glucitol 2-[2-methyl-3-(perfluoromethyl)anilino]nicotinate:
Test		: Maximization Test
	es of exposure	: Dermal
Speci	es ssment	: Guinea pig : Does not cause skin sensitization.
Resu		: negative
Not c	n <b>cell mutagenicity</b> lassified based on av ponents:	ailable information.
Florfe	enicol:	
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: DNA damage and repair, unscheduled DNA syn- thesis in mammalian cells (in vitro) Test system: rat hepatocytes Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
Geno	toxicity in vivo	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative



ersion .1	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014			
2-Pyr	rolidone:					
-	toxicity in vitro	: Test Type: Bao Result: negativ	cterial reverse mutation assay (AMES) /e			
		Method: OECI Result: negativ	vitro mammalian cell gene mutation test D Test Guideline 476 ve ed on data from similar materials			
			romosome aberration test in vitro D Test Guideline 473 /e			
Geno	toxicity in vivo	cytogenetic as Species: Mous				
			D Test Guideline 474			
Malic	Acid:					
Geno	toxicity in vitro	: Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) /e			
			vitro mammalian cell gene mutation test D Test Guideline 476 ve			
		0	ed on data from similar materials			
		Test Type: Ch Result: negativ	romosome aberration test in vitro /e			
		Remarks: Based on data from similar materials				
1-Dec	oxy-1-(methylamino	-D-glucitol 2-[2-meth	yl-3-(perfluoromethyl)anilino]nicotinate:			
	toxicity in vitro		cterial reverse mutation assay (AMES)			
		Test Type: in v Test system: n Result: positive	nouse lymphoma cells			
			romosomal aberration Chinese hamster ovary cells e			
		Test Type: in v Test system: E Result: positive	scherichia coli			



sion	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
	cell mutagenicity - ssment	: Weight of evid cell mutagen.	ence does not support classification as a ger
Carci	nogenicity		
Not cl	assified based on av	ailable information.	
<u>Comp</u>	oonents:		
Florfe	enicol:		
Speci	es	: Rat	
Applic	ation Route	: oral (gavage)	
Expos	sure time	: 2 Years	
Resul	t	: negative	
Targe	t Organs	: Liver, Testes	
Speci		: Mouse	
	ation Route	: oral (gavage)	
	sure time	: 2 Years	
Resul	-	: negative	
l arge	t Organs	: Testes, Blood	
2-Pyr	rolidone:		
Speci	es	: Mouse	
•	ation Route	: Ingestion	
	sure time	: 18 month(s)	
Resul		: negative	
Rema	irks	: Based on data	from similar materials
1-Dec	oxv-1-(methvlamino	)-D-alucitol 2-[2-meth	yl-3-(perfluoromethyl)anilino]nicotinate:
Speci		: Rat	), , (herring), and a second
	ation Route	: oral (feed)	
	sure time	: 104 w	
LOAE		: 2 mg/kg body	veight
Resul		: negative	longin
	t Organs	: Gastrointestina	l tract
Rema			city observed in testing
Speci	es	: Mouse	
	ation Route	: oral (feed)	
	sure time	: 97 w ́	
NÖAE		: 0.6 mg/kg bod	y weight
Resul		: negative	
•	t Organs	: Gastrointestina	
Rema	ırks	: Significant toxi	city observed in testing
IARC			ent at levels greater than or equal to 0.1% is r confirmed human carcinogen by IARC.
OSH <i>A</i>	•	nent of this product pre s list of regulated carci	sent at levels greater than or equal to 0.1% i nogens.
			ent at levels greater than or equal to 0.1% is



Version 8.1	Revision Date: 03/23/2020		9S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
	identified as a	i kno	own or anticipated	carcinogen by NTP.
May d	oductive toxicity lamage fertility. May dar ponents:	nag	e the unborn child.	
Florfe	enicol:			
Effect	s on fertility	:	Species: Rat Application Route Fertility: LOAEL:	eneration reproduction toxicity study e: Oral 12 mg/kg body weight d pup survival, reduced lactation
Effect	s on fetal development	:	Species: Rat General Toxicity I Embryo-fetal toxic Result: No teratog	vo-fetal development Maternal: NOAEL: 4 mg/kg body weight city.: LOAEL: 40 mg/kg body weight genic effects., Fetotoxicity. ects were seen only at maternally toxic dos-
			Species: Mouse Application Route General Toxicity	Maternal: NOAEL: 120 mg/kg body weight city.: LOAEL: 40 mg/kg body weight
Repro sessm	oductive toxicity - As- nent	:	fertility, based on	f adverse effects on sexual function and animal experiments., Some evidence of n development, based on animal
2-Pyr	rolidone:			
•	s on fertility	:	Species: Rat Application Route Result: positive	eneration reproduction toxicity study :: Ingestion on data from similar materials
Effect	s on fetal development	:	Test Type: Embry Species: Rat Application Route Result: positive	vo-fetal development : Ingestion
Repro sessm	oductive toxicity - As- nent	:	fertility, based on	adverse effects on sexual function and animal experiments., Clear evidence of development, based on animal
Malic	Acid:			
	s on fertility	:	Test Type: Two-g	eneration reproduction toxicity study



Version 8.1	Revision Date: 03/23/2020		9S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
			Species: Rat Application Route Result: negative	: Ingestion
Effect	Effects on fetal development :		Test Type: Embry Species: Rat Application Route Result: negative	vo-fetal development :: Ingestion
1-Dec	oxy-1-(methylamino)-D	-glu	citol 2-[2-methyl-	3-(perfluoromethyl)anilino]nicotinate:
	ts on fertility	:	Test Type: Two-g Species: Rat Application Route General Toxicity I Symptoms: No fe	eneration reproduction toxicity study : Oral Parent: LOAEL: 1 - 1.5 mg/kg body weight tal abnormalities. s on fertility and early embryonic
Effect	Effects on fetal development :		Embryo-fetal toxic Result: Embryoto	
			Species: Rabbit Application Route General Toxicity I Embryo-fetal toxic Result: Embryoto	vo-fetal development e: Oral Maternal: LOAEL: 3 mg/kg body weight city.: NOAEL: 3 mg/kg body weight xic effects and adverse effects on the tected only at high maternally toxic doses
	-single exposure	bla	information	
_	lassified based on availa	adle	information.	
Com	ponents:			

## 1-Deoxy-1-(methylamino)-D-glucitol 2-[2-methyl-3-(perfluoromethyl)anilino]nicotinate:

Assessment

: May cause respiratory irritation.

## STOT-repeated exposure

Causes damage to organs (Liver, Brain, Testis, Spinal cord, Blood, gallbladder, Gastrointestinal tract, Kidney) through prolonged or repeated exposure.

## Components:

Florfenicol:	
Target Organs Assessment	Liver, Brain, Testis, Spinal cord, Blood, gallbladder Causes damage to organs through prolonged or repeated exposure.



ersion I	Revision Date: 03/23/2020	SDS Number:Date of last issue: 12/12/201928058-00016Date of first issue: 11/04/2014
Targe	oxy-1-(methylamino) et Organs ssment	<ul> <li><b>)-D-glucitol 2-[2-methyl-3-(perfluoromethyl)anilino]nicotinate:</b></li> <li>Gastrointestinal tract, Kidney, Blood</li> <li>Causes damage to organs through prolonged or repeated exposure.</li> </ul>
Repe	ated dose toxicity	
<u>Com</u> r	oonents:	
Florfe	enicol:	
		: Dog : 3 mg/kg : 13 Weeks : Liver, Testis, Brain, Spinal cord
		: Mouse : 200 mg/kg : 13 Weeks : Liver, Testis
		: Rat : 30 mg/kg : 13 Weeks : Liver, Testis
	EL	: Dog : 3 mg/kg : 12 mg/kg : 52 Weeks : Liver, gallbladder
	EL	: Rat : 1 mg/kg : 3 mg/kg : 52 Weeks : Testis
2-Pyr	rolidone:	
Specie NOAE Applic	es EL cation Route sure time	<ul> <li>Rat</li> <li>207 mg/kg</li> <li>Ingestion</li> <li>3 Months</li> <li>OECD Test Guideline 408</li> </ul>
Malic	Acid:	
		: Rat : > 250 mg/kg : Ingestion : 104 Weeks

Species

: Rat



Version 8.1	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014		
Expo		: 2 mg/kg : < 4 mg/kg : Oral : 6 w : Gastrointestina	l tract		
Expo		: Rat : 1 mg/kg : Oral : 1 y : Gastrointestina	: 1 mg/kg : Oral		
Expo		: Monkey : 15 mg/kg : Oral : 90 d : Gastrointestina	l tract, Blood		
Expo		: Rabbit : 80 mg/kg : Dermal : 21 d : Severe irritatior	ı		
Expo Targe		: Dog : 11 mg/kg : Oral : 9 d : Gastrointestina : Vomiting	l tract		
Not c	ration toxicity lassified based on avai rience with human ex				
-	ponents:				
Inhal Skin	ation contact contact	: Symptoms: res : Symptoms: Ski : Symptoms: Sev			

## **SECTION 12. ECOLOGICAL INFORMATION**

:

## Ecotoxicity

Ingestion

## Components:

## Florfenicol:

Toxicity to fish

: LC50 (Lepomis macrochirus (Bluegill sunfish)): > 830 mg/l Exposure time: 96 h Method: FDA 4.11

Symptoms: Gastrointestinal disturbance, bleeding, hyperten-

sion, Kidney disorders



Version 8.1	Revision Date: 03/23/2020		9S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014	
			LC50 (Oncorhync Exposure time: 96 Method: FDA 4.1		
	Toxicity to daphnia and other aquatic invertebrates		EC50 (Daphnia magna (Water flea)): > 330 mg/l Exposure time: 48 h Method: OECD Test Guideline 202		
Toxicit <sub>)</sub> plants	Toxicity to algae/aquatic plants		EC50 (Pseudokirchneriella subcapitata (green algae)): mg/l Exposure time: 14 d Method: FDA 4.01		
			NOEC (Pseudokir mg/l Exposure time: 14 Method: FDA 4.01		
			IC50 (Skeletonem Exposure time: 72 Method: ISO 1025		
			NOEC (Skeletone Exposure time: 72 Method: ISO 1025		
			EC50 (Lemna gib Exposure time: 7 Method: OECD Te		
			NOEC (Lemna gil Exposure time: 7 Method: OECD Te		
			EC50 (Navicula p Exposure time: 72 Method: OECD Te		
			NOEC (Navicula p Exposure time: 72 Method: OECD Te		
			EC50 (Anabaena Exposure time: 72 Method: OECD Te		
			NOEC (Anabaena Exposure time: 72 Method: OECD Te		
Toxicity	y to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 32 Method: OECD Te		



/ersion 8.1	Revision Date: 03/23/2020		0S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014	
Toxicity to daphnia and other aquatic invertebrates (Chron-ic toxicity)		:	: NOEC (Daphnia magna (Water flea)): 1.5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211		
2-Pyr	rolidone:				
-	Toxicity to fish		LC50 (Danio rerio (zebra fish)): > 4,600 - 10,000 mg/l Exposure time: 96 h Method: OECD Test Guideline 203		
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 500 mg/l Exposure time: 48 h		
Toxic plants	ity to algae/aquatic	:	ErC50 (Desmodes Exposure time: 72	smus subspicatus (green algae)): > 500 mg ! h	
			EC10 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 22.2 mg/l ! h	
Тохіс	Toxicity to microorganisms		EC50: > 1,000 mg/l Exposure time: 30 min Method: OECD Test Guideline 209		
Malic	Acid:				
Toxic	ity to fish	:	Exposure time: 96 Method: OECD Te		
	ity to daphnia and other ic invertebrates	:	: EC50 (Daphnia magna (Water flea)): 240 mg/l Exposure time: 48 h		
	Toxicity to algae/aquatic plants		mg/l Exposure time: 72 Test substance: N Method: OECD Te	eutralized product	
			mg/l Exposure time: 72 Test substance: N Method: OECD Te	eutralized product	
Toxic	ity to microorganisms	:	EC50: > 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 Remarks: Based on data from similar materials		
1-Dec	oxy-1-(methylamino)-D	-glu	citol 2-[2-methvl-3	-(perfluoromethyl)anilino]nicotinate:	
	ity to fish	:		acrochirus (Bluegill sunfish)): 28 mg/l	



rsion	Revision Date: 03/23/2020		S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
			Method: FDA 4.1	1
			LC50 (Oncorhynd Exposure time: 90 Method: FDA 4.1	chus mykiss (rainbow trout)): 5.5 mg/l 5 h 1
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 44 Method: FDA 4.04	
Toxicity to algae/aquatic plants		:	NOEC (Microcystis aeruginosa (blue-green algae)): 97 mg Exposure time: 13 d Method: FDA 4.01	
			NOEC (Selenastr Exposure time: 12	um capricornutum (green algae)): 96 mg 2 d
Persi	stence and degradabil	ity		
Com	oonents:			
-	<b>rolidone:</b> gradability	:	Result: Readily b Remarks: Based	odegradable. on data from similar materials
	Acid: gradability	:		odegradable. est Guideline 301C on data from similar materials
	<b>oxy-1-(methylamino)-D</b> ity in water	-glu :	<b>citol 2-[2-methyl-</b> Hydrolysis: 0 %(2	<b>3-(perfluoromethyl)anilino]nicotinate:</b> 8 d)
Bioad	cumulative potential			
Com				
Com	oonents:			
	<u>oonents:</u> enicol:			
<b>Florf</b> e Partiti		:	log Pow: 0.373	
Florfe Partiti octan	enicol: ion coefficient: n-	:	log Pow: 0.373	
Florfe Partiti octan <b>2-Pyr</b> Partiti	enicol: ion coefficient: n- ol/water	:	log Pow: -0.71	est Guideline 107
Florfe Partiti octan 2-Pyr Partiti octan	enicol: ion coefficient: n- ol/water <b>rolidone:</b> ion coefficient: n-	:	log Pow: -0.71	est Guideline 107
Florfe Partiti octan Partiti octan Malic Partiti	enicol: ion coefficient: n- ol/water rolidone: ion coefficient: n- ol/water	:	log Pow: -0.71	est Guideline 107
Florfe Partiti octan Partiti octan Malic Partiti octan	enicol: ion coefficient: n- ol/water rolidone: ion coefficient: n- ol/water Acid: ion coefficient: n- ol/water	:	log Pow: -0.71 Method: OECD T log Pow: -1.26	est Guideline 107 3-(perfluoromethyl)anilino]nicotinate:



/ersion .1	Revision Date: 03/23/2020		S Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
Mobil	ity in soil			
Comp	onents:			
Distrib		-glu :	<b>citol 2-[2-methyl</b> log Koc: 1.92	-3-(perfluoromethyl)anilino]nicotinate:
	adverse effects ta available			
ECTION	13. DISPOSAL CONSI	DER	ATIONS	
Disno	sal methods			
Waste	e from residues minated packaging	:	Empty container handling site for	cordance with local regulations. s should be taken to an approved waste recycling or disposal. specified: Dispose of as unused product.
ECTION	14. TRANSPORT INFO	RM	ATION	
Intern	ational Regulations			
UNRT UN nu Prope		:	N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID,
Class Packir Labels	ng group	:	(Florfenicol) 9 III 9	
<b>IATA-</b> UN/ID Prope	-	:		hazardous substance, liquid, n.o.s.
Labels	ng group s ng instruction (cargo	:	(Florfenicol) 9 III Miscellaneous 964	
aircraf Packir ger air	t) ng instruction (passen-	:	964 yes	
	-Code	•	yes	
UN nu		:	N.O.S.	ALLY HAZARDOUS SUBSTANCE, LIQUID,
Labels EmS (		:	(Florfenicol) 9 III 9 F-A, S-F yes	





Version 8.1	Revision Date: 03/23/2020		DS Number: 058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
Not a	sport in bulk accordi applicable for product a nestic regulation	-		POL 73/78 and the IBC Code
Prop Clas Pack Labe ERG	D/NA number er shipping name s ting group els Code ne pollutant		(Florfenicol) 9 III CLASS 9 171 yes(Florfenicol) Above applies or liters., Shipment however it may b	hazardous substance, liquid, n.o.s. hly to containers over 119 gallons or 450 by ground under DOT is non-regulated; be shipped per the applicable hazard acilitate multi-modal transport involving ICAO

## Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## **SECTION 15. REGULATORY INFORMATION**

## **EPCRA - Emergency Planning and Community Right-to-Know**

## **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

## SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

## SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	<ul> <li>Acute toxicity (any route of exposure)</li> <li>Reproductive toxicity</li> <li>Specific target organ toxicity (single or repeated exposure)</li> <li>Serious eye damage or eye irritation</li> </ul>
SARA 313	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## **US State Regulations**


Pennsylvania Right To Know	
Triacetin	102-76-1
2-Pyrrolidone	616-45-5
Florfenicol	73231-34-2

The ingredients of this product are reported in the following inventories:



Version 8.1	Revision Date: 03/23/2020	SDS Number: 28058-00016	Date of last issue: 12/12/2019 Date of first issue: 11/04/2014
AICS		: not determined	
DSL		: not determined	
IECSC	>	: not determined	

## **SECTION 16. OTHER INFORMATION**



## Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice: HMIS - Hazardous Materials Identification System: IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable



Version	Revision Date:	SDS Number:	Date of last issue: 12/12/2019
8.1	03/23/2020	28058-00016	Date of first issue: 11/04/2014

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 03/23/2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8